Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Other Announcement

Jenburkt Pharmaceuticals clarified its shares are permitted to trade on NSE without a listing application. The shares remain listed on BSE under the Permitted to Trade category.

Jenburkt Pharmaceuticals Management Change

Mr. Vinay Bhatt, Senior Vice President- International Business, has resigned from Jenburkt Pharmaceuticals Limited effective September 18, 2026, due to personal reasons.

Jenburkt Pharmaceuticals Annual General Meeting

Jenburkt Pharmaceuticals held its 41st Annual General Meeting on 4th September, 2026, to discuss financial statements, dividend declaration, and director appointments.

Jenburkt Pharmaceuticals Management Change

Jenburkt Pharmaceuticals elevated Shri Prem Ashish Bhuta to Associate Vice President – Strategic Initiatives. He is now classified as Senior Management Personnel effective September 4, 2026.

Jenburkt Pharmaceuticals Q1 FY27 Results: Net Profit ₹5.9 Cr, Down 24.4% YoY

Jenburkt Pharmaceuticals Ltd reported revenue from operations of ₹35.5 Cr (+0.0% YoY) and net profit of ₹5.9 Cr (-24.4% YoY) for Q1 FY27.

Key figure

Net profit ₹5.9 Cr · -24.4% YoY

Jenburkt Pharmaceuticals Q4 FY26 Results: Net Profit ₹34.7 Cr, Up 8.1% YoY

Jenburkt Pharmaceuticals Ltd reported revenue from operations of ₹168.7 Cr (+11.2% YoY) and net profit of ₹34.7 Cr (+8.1% YoY) for Q4 FY26.

Key figure

Net profit ₹34.7 Cr · +8.1% YoY

Jenburkt Pharmaceuticals Q4 FY26 Results: Net Profit ₹10.8 Cr, Up 27.1% YoY

Jenburkt Pharmaceuticals Ltd reported revenue from operations of ₹44.6 Cr (+8.8% YoY) and net profit of ₹10.8 Cr (+27.1% YoY) for Q4 FY26.

Key figure

Net profit ₹10.8 Cr · +27.1% YoY